# C Reactive Protein Testing Market > C reactive protein testing Market Research Report Information By Assay Type (Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assays, and Others), By Application (Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.9% - **2024:** $ 3.2 Billion - **2025:** $ 3.42 Billion - **2035:** $ 6.66 Billion - **Key Players:** Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Beckman Coulter (US), QuidelOrtho Corporation (US), Bio-Rad Laboratories (US) **Report ID:** MRFR/LS/10636-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/c-reactive-protein-testing-market-12157 --- ## Market Summary ## **C-Reactive Protein Testing Market Overview** As per MRFR analysis, the C Reactive Protein Testing Market Size was estimated at 3.2 (USD Billion) in 2024. The C Reactive Protein Testing Market Industry is expected to grow from 3.42 (USD Billion) in 2025 to 6.23 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.90% during the forecast period (2025 - 2034).  Increasing elderly population and need for healthcare services globally are the key market drivers enhancing the market growth.  ## **C-Reactive Protein Testing Market Trends** Market CAGR for C reactive protein testing is being driven by the rising chronic illnesses. The rising frequency of endometriosis in women worldwide, the rise in chronic illnesses such as inflammatory disorders, rheumatoid arthritis, and cardiovascular disease, and the growing need for healthcare services.  For instance, 20.1 million persons aged 20 and older had coronary artery disease (CAD) in 2021, according to statistics released by the Centres for Disease Control and Prevention (CDC) and updated in October 2022.  Additionally, it has been stated that about 805,000 Americans get a heart attack each year. Increased CRP testing used to assess cardiovascular disease risk results from a rise in the prevalence of cardiovascular illnesses, fueling market expansion.  The development of portable bioanalytical tests with high specificity and sensitivity, quick reaction times, and multiplexing capabilities for on-site precise disease diagnosis and monitoring are also anticipated to benefit from improvements in nanotechnological techniques. Throughout the projection period, these developments are anticipated to increase demand for CRP testing.  The primary drivers of the C-reactive Protein Testing market are the rising prevalence of cardiovascular disorders worldwide and research & development to modernize the C-reactive Protein Testing techniques. According to a study done in 2019 by the American Heart Association (AHA), cardiovascular disorders cause more than 801,000 deaths in the US and about 2,200 patient fatalities. An aging population and a rise in diabetes mellitus incidence are also driving the market for C-reactive Protein Testing. Gastrointestinal illnesses and the associated demand for effective disease testing techniques have driven the industry. Gastrointestinal illnesses and the associated demand for effective disease testing techniques have driven the industry.  Adult patients with a diagnosis of a respiratory tract infection should undergo POC CRP testing in primary care, according to the National Institute of Health and Care Excellence.  The industry is being driven by initiatives done by government organizations to raise awareness and adoption of point of care. An increase in funding and investments for organizations doing research operations in the field and a boost for market expansion. The top cause of mortality globally, according to the World Heart Federation, is coronary heart disease.  According to estimates, coronary heart disease claims the lives of 3.4 million women and 3.8 million men annually. Due to their diverse optical characteristics, plasmonic nanoparticles (PNPs) are one of the technologies that may be employed for biosensing applications.. Thus, driving the C reactive protein testing market revenue. ## **C-Reactive Protein Testing Market Segment Insights** ### **C-Reactive Protein Testing Assay Type Insights**  Based on type, the market segments of C reactive protein testing includes enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunoturbidimetric assays, and others. The enzyme-linked immunosorbent assay (ELISA) segment dominated the market, accounting for 35% of market revenue.  The rise in the market is ascribed to ELISA's many advantages, including the fact that it is an easy, fast, accurate, and reliable analytical technique for identifying and measuring human C-reactive protein in the blood. The development of this market is also significantly influenced by the rise in the incidence of chronic and infectious illnesses, the rise in the geriatric population, the surge in product releases, and collaborations with other market participants for the marketing of ELISA tests. ### **C-Reactive Protein Testing Application Insights** The C-Reactive protein testing market segmentation, based on Application, includes diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease, and others. The cardiovascular disease category generated the most income. The increase in the prevalence of CVDs is the main factor driving market development.  A sedentary lifestyle, hypertension, obesity, and diabetes are a few risk factors for CVDs. C-reactive protein is the noninvasive biomarker for inflammation in CVDs that has been most fully studied, and there are currently several hs-CRP assays available. **Figure 1: C reactive protein testing Market, by Application, 2022 & 2032 (USD Billion)**  _Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_ ###  **C Reactive Protein Testing Regional Insights** By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American C-Reactive protein testing market will dominate this market, with an increase in the adoption of cutting-edge technology and a significant focus on clinical research in North America. Given how prevalent cancer is in the United States, CRP testing is often employed. Further, the major countries studied in the market report are The US, Canada, German, Italy, Spain, China, Japan, France, the UK, India, Australia, South Korea, and Brazil. **Figure 2: C REACTIVE PROTEIN TESTING MARKET SHARE BY REGION 2022 (USD Billion)**  _Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_ Europe has the second-largest market share for C-reactive protein testing. The prevalence of a well-established healthcare infrastructure, rising rates of CVD, rheumatoid arthritis, and other inflammatory diseases, and a favorable reimbursement environment. Furthermore, the German market of C reactive protein testing dominated, while the UK market of C reactive protein testing grew fastest in Europe. From 2023 to 2032, the Asia-Pacific C reactive protein testing Market will develop at the quickest CAGR. An increase in hospitals and a rise in hospital admissions for emergency treatment are driving the market's expansion in this area. A key factor driving market development is the rise in traffic accidents, which raises the patient population. Furthermore, China's market of C reactive protein testing had the highest market share. In contrast, the Asia-Pacific region's market of C reactive protein testing in India was the one that was growing the quickest. ## **C Reactive Protein Testing Key Market Players & Competitive Insights** Leading market companies are extensively spending R&D on increasing their product lines, which will help the market of C reactive protein testing grow even more. Important market developments include new product releases, contractual agreements, acquisitions and mergers, greater investments, and collaboration with other organizations. The C reactive protein testing industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate. Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide C reactive protein testing industry to serve clients and expand the market sector. The C reactive protein testing industry has provided some of the most important benefits recently. LumiraDx, Trivitron Healthcare's, and other major competitors in the market of C reactive protein testing are seeking to improve market demand by investing in R&D efforts. A next-generation point-of-care diagnostics business called LumiraDx is revolutionizing community-based healthcare. Since its establishment in 2014, LumiraDx has produced and sold a revolutionary diagnostic Platform that enables a wide range of tests with point-of-care performance that is on par with a lab's.  Governments and top healthcare organizations use LumiraDx diagnostic testing systems in clinics, urgent care centers, doctor's offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness and illness. On the LumiraDx Platform, LumiraDx offers more than 30 tests for infectious illnesses, cardiovascular diseases, diabetes, and coagulation disorders available or under development.  Additionally, LumiraDx offers a wide range of quick, precise, and reasonably priced COVID-19 testing options from the lab to the point of need. In January 2022, LumiraDx announced the C-reactive protein (CRP) Test CE Marking. The LumiraDx CRP Test measures C-reactive protein quantitatively and provides findings in four minutes. It is a tiny, portable, fully automated microfluidic immunoassay test. CRP testing offers crucial information to diagnose and assess infection and inflammation. Trivitron Healthcare's history as a medical technology firm offering cost-effective solutions has been a fascinating source of inspiration for many healthcare professionals since 1997. Hospitals, private healthcare practitioners, independent clinics and laboratories, long-term care facilities, renal care centers, and other structures offering healthcare solutions are the target markets for Trivitron's goods. Trivitron, a leader in the industry, is continually looking for new technical advancements to provide better clinical advantages at a reduced price.  In June 2021, In order to simplify COVID-19 diagnosis in remote, urban, and rural areas of India, Trivitron Healthcare created a mobile laboratory. The local lab offers RT-PCR assays, fast antigen tests, CLIA/Elisa IgG and IgM antibody tests, and CLIA/Elisa tests for inflammatory indicators, including D-Dimer, CRP and IL-6. ### **Key Companies in the Market of C Reactive Protein Testing Include** ## C Reactive Protein Testing Industry Developments - **Q2 2024: C-reactive protein testing: Powering precision in inflammation and cardiovascular diagnostics** In 2024, the C-reactive protein (CRP) testing market saw a surge in direct-to-home testing services, with new CRP testing kits designed for at-home use expanding access to diagnostics for patients managing long-term health conditions or residing in remote areas. ## **C Reactive Protein Testing Market Segmentation** ### **C reactive protein testing Assay Type Outlook** ### **C reactive protein testing Application Outlook** ### **C reactive protein testing Regional Outlook** ## Market Drivers ### Rising Incidence of Chronic Diseases The increasing prevalence of chronic diseases such as cardiovascular disorders and diabetes is a notable driver for the C-Reactive Protein Testing Market. As these conditions are often associated with elevated levels of C-Reactive Protein (CRP), healthcare providers are increasingly utilizing CRP testing as a diagnostic tool. According to recent data, the incidence of chronic diseases has been on the rise, leading to a heightened demand for effective monitoring and management strategies. This trend suggests that the C-Reactive Protein Testing Market is likely to experience growth as healthcare systems prioritize early detection and intervention. Furthermore, the integration of CRP testing into routine health assessments may enhance patient outcomes, thereby reinforcing the market's expansion. ### Advancements in Diagnostic Technologies Technological innovations in diagnostic testing are significantly influencing the C-Reactive Protein Testing Market. The development of high-sensitivity CRP assays has improved the accuracy and reliability of CRP measurements, making them more accessible for clinical use. These advancements enable healthcare professionals to better assess inflammation levels and associated risks. Moreover, the introduction of point-of-care testing devices allows for rapid results, facilitating timely clinical decisions. As a result, the market is witnessing an increase in the adoption of these advanced testing methods, which could potentially lead to a broader application of CRP testing in various healthcare settings. The ongoing research and development in this field may further enhance the capabilities of CRP testing, thereby driving market growth. ### Increased Focus on Preventive Healthcare The growing emphasis on preventive healthcare is a significant factor propelling the C-Reactive Protein Testing Market. As healthcare systems shift towards proactive management of health, CRP testing is being recognized for its role in identifying individuals at risk of developing chronic inflammatory conditions. This preventive approach aligns with global health initiatives aimed at reducing the burden of diseases. Data indicates that healthcare expenditures on preventive measures are increasing, which may lead to a higher demand for CRP testing as part of routine health screenings. Consequently, the C-Reactive Protein Testing Market is likely to benefit from this trend, as more individuals seek early detection and management of potential health issues. ### Regulatory Support for Diagnostic Testing Regulatory bodies are increasingly recognizing the importance of diagnostic testing, including C-Reactive Protein Testing, in clinical practice. This support is evident in the streamlined approval processes for new testing technologies and the establishment of guidelines that promote the use of CRP testing in various healthcare settings. Such regulatory frameworks are likely to enhance the credibility and adoption of CRP testing among healthcare providers. Furthermore, as regulations evolve to support innovative diagnostic solutions, the C-Reactive Protein Testing Market may experience accelerated growth. The alignment of regulatory policies with advancements in testing methodologies could foster a more robust market environment, encouraging investment and development in CRP testing solutions. ### Growing Research in Inflammatory Biomarkers The expanding body of research focused on inflammatory biomarkers is contributing to the growth of the C-Reactive Protein Testing Market. As scientists and clinicians explore the relationship between inflammation and various diseases, CRP has emerged as a key biomarker for assessing inflammatory responses. This research is not only enhancing the understanding of disease mechanisms but also promoting the clinical utility of CRP testing in diverse medical fields. The increasing number of studies published on CRP and its implications in health may lead to greater acceptance and utilization of CRP testing in clinical practice. This trend suggests a promising future for the C-Reactive Protein Testing Market as it aligns with the evolving landscape of personalized medicine. ## Future Outlook The C-Reactive Protein Testing Market is projected to grow at a 6.9% CAGR from 2025 to 2035, driven by increasing chronic disease prevalence and advancements in diagnostic technologies. **New opportunities:** - Development of point-of-care testing devices for rapid results - Integration of AI for enhanced data analysis and patient management - Expansion into emerging markets with tailored diagnostic solutions By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare demands. ## Segment Insights ### By Assay Type: Chemiluminescence Immunoassay (Largest) vs. Enzyme-linked Immunosorbent Assay (Fastest-Growing) In the C-Reactive Protein Testing Market, the [Chemiluminescence Immunoassay (CLIA)](https://www.marketresearchfuture.com/reports/chemiluminescence-immunoassay-market-43371) accounts for the largest segment share, reflecting its widespread adoption due to sensitivity and rapid results. Following closely, the Enzyme-linked Immunosorbent Assay (ELISA) is also significant, known for its robustness in different settings. Other methods such as immunoturbidimetric assays make up a smaller portion of the market, but they cater to specific testing needs. This diverse distribution is essential as different assay types serve various applications, from clinical laboratories to point-of-care settings. In terms of growth trends, the ELISA segment is currently experiencing a rapid rise in adoption, primarily due to advancements in technology and increasing demand for precise and efficient testing methods. Market drivers also include the rising prevalence of chronic diseases and ongoing research initiatives focusing on inflammatory markers. There is a notable shift towards automated systems and point-of-care testing, which further augments the market for specific assay types, particularly the ELISA, which is becoming more integrated into routine diagnostics. Chemiluminescence Immunoassay (Dominant) vs. Enzyme-linked Immunosorbent Assay (Emerging) The Chemiluminescence Immunoassay (CLIA) continues to dominate the C-Reactive Protein Testing Market due to its high sensitivity and ability to deliver results quickly. This method leverages the properties of light-emitting reactions to detect the presence of CRP in samples, making it prevalent in both clinical and research environments. Conversely, the Enzyme-linked Immunosorbent Assay (ELISA) is emerging as a pivotal player, driven by recent technological advancements that enhance its accuracy and efficiency. While historically it has been regarded as a standard method, its rejuvenation offers significant potential for growth, especially in point-of-care testing scenarios. Both assay types are crucial for addressing the escalating demand for reliable and timely CRP testing across diverse healthcare settings. ### By Application: Cardiovascular Disease (Largest) vs. Rheumatoid Arthritis (Fastest-Growing) In the C-Reactive Protein Testing Market, the application segment reveals that Cardiovascular Disease holds the largest share, primarily driven by rising prevalence and increased awareness of heart-related conditions. This application significantly influences overall market dynamics due to its critical role in indicating cardiovascular inflammation, thus supporting diagnostic and therapeutic strategies. Following closely is the Rheumatoid Arthritis segment, recognized as the fastest-growing category, owing to heightened incidences and better diagnostic capabilities. The awareness and validation of CRP testing as a reliable marker for arthritic conditions propel this segment forward as healthcare providers look for effective monitoring and management techniques. Cardiovascular Disease (Dominant) vs. Rheumatoid Arthritis (Emerging) Cardiovascular Disease is characterized by its substantial market demand, being a primary focus in the healthcare sector due to its correlation with severe health outcomes. This segment thrives on established protocols that incorporate C-Reactive Protein testing to monitor inflammation, which serves as a crucial marker for predicting cardiovascular events. In contrast, Rheumatoid Arthritis is emerging rapidly, driven by advancements in testing technologies and increasing rates of diagnosis. The rising awareness surrounding autoimmune conditions has led to a surge in the adoption of CRP testing, positioning it as a key player in disease management. This dynamic growth is further supported by ongoing research that reinforces the validity of CRP as a biomarker for treatment efficacy. ## Regional Market Share Analysis By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American C-Reactive protein testing market will dominate this market, with an increase in the adoption of cutting-edge technology and a significant focus on clinical research in North America. Given how prevalent cancer is in the United States, CRP testing is often employed. Further, the major countries studied in the market report are The US, Canada, German, Italy, Spain, China, Japan, France, the UK, India, Australia, South Korea, and Brazil. **Figure 2: C REACTIVE PROTEIN TESTING MARKET SHARE BY REGION 2022 (USD Billion)**  Europe has the second-largest market share for C-reactive protein testing. The prevalence of a well-established healthcare infrastructure, rising rates of CVD, rheumatoid arthritis, and other inflammatory diseases, and a favorable reimbursement environment. Furthermore, the German market of C reactive protein testing dominated, while the UK market of C reactive protein testing grew fastest in Europe. From 2023 to 2032, the Asia-Pacific C reactive protein testing Market will develop at the quickest CAGR. An increase in hospitals and a rise in hospital admissions for emergency treatment are driving the market's expansion in this area. A key factor driving market development is the rise in traffic accidents, which raises the patient population. Furthermore, China's market of C reactive protein testing had the highest market share. In contrast, the Asia-Pacific region's market of C reactive protein testing in India was the one that was growing the quickest. ## Competitive Benchmarking Leading market companies are extensively spending R&D on increasing their product lines, which will help the market of C reactive protein testing grow even more. Important market developments include new product releases, contractual agreements, acquisitions and mergers, greater investments, and collaboration with other organizations. The C reactive protein testing industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate. Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide C reactive protein testing industry to serve clients and expand the market sector. The C reactive protein testing industry has provided some of the most important benefits recently. LumiraDx, Trivitron Healthcare's, and other major competitors in the market of C reactive protein testing are seeking to improve market demand by investing in R&D efforts. A next-generation point-of-care diagnostics business called LumiraDx is revolutionizing community-based healthcare. Since its establishment in 2014, LumiraDx has produced and sold a revolutionary diagnostic Platform that enables a wide range of tests with point-of-care performance that is on par with a lab's.  Governments and top healthcare organizations use LumiraDx diagnostic testing systems in clinics, urgent care centers, doctor's offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness and illness. On the LumiraDx Platform, LumiraDx offers more than 30 tests for infectious illnesses, cardiovascular diseases, diabetes, and coagulation disorders available or under development.  Additionally, LumiraDx offers a wide range of quick, precise, and reasonably priced COVID-19 testing options from the lab to the point of need. In January LumiraDx announced the C-reactive protein (CRP) Test CE Marking. The LumiraDx CRP Test measures C-reactive protein quantitatively and provides findings in four minutes. It is a tiny, portable, fully automated microfluidic immunoassay test. CRP testing offers crucial information to diagnose and assess infection and inflammation. Trivitron Healthcare's history as a medical technology firm offering cost-effective solutions has been a fascinating source of inspiration for many healthcare professionals since 1997. Hospitals, private healthcare practitioners, independent clinics and laboratories, long-term care facilities, renal care centers, and other structures offering healthcare solutions are the target markets for Trivitron's goods. Trivitron, a leader in the industry, is continually looking for new technical advancements to provide better clinical advantages at a reduced price.  In June 2021, In order to simplify COVID-19 diagnosis in remote, urban, and rural areas of India, Trivitron Healthcare created a mobile laboratory. The local lab offers RT-PCR assays, fast antigen tests, CLIA/Elisa IgG and IgM antibody tests, and CLIA/Elisa tests for inflammatory indicators, including D-Dimer, CRP and IL-6. ## Recent News & Developments - **Q2 2024: C-reactive protein testing: Powering precision in inflammation and cardiovascular diagnostics** In 2024, the C-reactive protein (CRP) testing market saw a surge in direct-to-home testing services, with new CRP testing kits designed for at-home use expanding access to diagnostics for patients managing long-term health conditions or residing in remote areas. ## Report Scope | MARKET SIZE 2024 | 3.196(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 3.417(USD Billion) | | MARKET SIZE 2035 | 6.66(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.9% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Beckman Coulter (US), QuidelOrtho Corporation (US), Bio-Rad Laboratories (US) | | Segments Covered | Assay Type, Application, Region | | Key Market Opportunities | Integration of advanced diagnostic technologies enhances accuracy in the C-Reactive Protein Testing Market. | | Key Market Dynamics | Rising demand for rapid diagnostic solutions drives innovation and competition in the C-Reactive Protein Testing market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the C-Reactive Protein Testing Market?** A: The C-Reactive Protein Testing Market was valued at 3.196 USD Billion in 2024. **Q: What is the projected market size for the C-Reactive Protein Testing Market by 2035?** A: The market is projected to reach 6.66 USD Billion by 2035. **Q: What is the expected CAGR for the C-Reactive Protein Testing Market during the forecast period?** A: The expected CAGR for the market from 2025 to 2035 is 6.9%. **Q: Which assay type segment shows the highest growth potential in the market?** A: The Chemiluminescence immunoassay (CLIA) segment is projected to grow from 1.0 to 2.0 USD Billion. **Q: How does the market for C-Reactive Protein Testing relate to cardiovascular disease?** A: The market for C-Reactive Protein Testing in cardiovascular disease applications was valued at 1.278 USD Billion in 2024 and is expected to grow significantly. **Q: Who are the key players in the C-Reactive Protein Testing Market?** A: Key players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific. **Q: What is the market valuation for diabetes-related C-Reactive Protein Testing?** A: The diabetes-related segment was valued at 0.639 USD Billion in 2024 and is projected to grow to 1.36 USD Billion. **Q: What is the growth trend for rheumatoid arthritis applications in the market?** A: The rheumatoid arthritis segment is expected to increase from 0.479 USD Billion in 2024 to 1.02 USD Billion by 2035. **Q: What are the projected values for immunoturbidimetric assays in the market?** A: Immunoturbidimetric assays are expected to grow from 0.8 USD Billion in 2024 to 1.5 USD Billion by 2035. **Q: What is the significance of the 'Others' category in the assay type segment?** A: The 'Others' category in the assay type segment is projected to grow from 0.196 USD Billion in 2024 to 0.66 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/c-reactive-protein-testing-market-12157*